Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation

Rajaiah Alexpandi (1) , Mathieu Gendrot (2, 3) , Gurusamy Abirami , Océane Delandre (2, 3) , Isabelle Fonta (2, 3) , Joel Mosnier (2, 3) , Richard Mariadasse , Jeyaraman Jeyakanthan , Shunmugiah Karutha Pandian , Bruno Pradines (2, 3, 4) , Arumugam Veera Ravi (1)

1 Alagappa University
2 IRBA - Institut de Recherche Biomédicale des Armées [Antenne Marseille]
3 VITROME - Vecteurs - Infections tropicales et méditerranéennes
4 IHU Marseille - Institut Hospitalier Universitaire Méditerranée Infection

Since the rapid spread of coronavirus disease (COVID-19) became a global pandemic, healthcare ministries around the world have recommended specific control methods such as quarantining infected peoples, identifying infections, wearing mask, and practicing hand hygiene. Since no effective treatment for COVID-19 has yet been discovered, a variety of drugs approved by Food and Drug Administration (FDA) have been suggested for repurposing strategy. In the current study, we predicted that doxycycline could interact with the nucleotide triphosphate (NTP) entry channel, and is therefore expected to hinder the viral replication of SARS-CoV-2 RNA-dependent RNA-polymerase (RdRp) through docking analysis. Further, the molecular dynamics results revealed that the RdRp-Doxycycline complex was structurally relatively stable during the dynamic period (100 ns), and its complex maintained close contact with their active catalytic domains of SARS-CoV-2 RdRp. The molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) calculation of binding free energy also showed that the doxycycline has worthy affinities with SARS-CoV-2 RdRp. As expected, doxycycline effectively inhibited the viral replication of IHU strains of SARS-CoV-2 (IHUMI-3 and IHUMI-6), identified from the hospitalized patients in IHU Méditerranée Infection (IHUMI), Marseille, France. Moreover, doxycycline inhibited the viral load in vitro at both on-entry and after viral entry of IHU variants of SARS-CoV-2. The results suggest that doxycycline exhibits strains-dependant antiviral activity against COVID-19. As a result, the current study concludes that doxycycline may be more effective in combination with other drugs for better COVID-19 treatment efficacy.

Mots clés: COVID-19; drug repurposing; doxycycline; SARS-CoV-2; in silico; in vitro

Domaines: Bactériologie; Cardiologie et système cardiovasculaire; Maladies émergentes; Maladies infectieuses; Parasitologie; Virologie

Rajaiah Alexpandi, Mathieu Gendrot, Gurusamy Abirami, Océane Delandre, Isabelle Fonta, et al.. Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation. Frontiers in Microbiology, 2022, 13, ⟨10.3389/fmicb.2022.757418⟩. ⟨hal-03758388⟩